Cisen Pharmaceutical Inkomsten in het verleden
Verleden criteriumcontroles 5/6
Cisen Pharmaceutical has been growing earnings at an average annual rate of 0.5%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 3.1% per year. Cisen Pharmaceutical's return on equity is 9.1%, and it has net margins of 12.4%.
Belangrijke informatie
0.5%
Groei van de winst
0.4%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 10.9% |
| Inkomstengroei | 3.1% |
| Rendement op eigen vermogen | 9.1% |
| Nettomarge | 12.4% |
| Laatste winstupdate | 30 Sep 2024 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Cisen Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 24 | 4,255 | 529 | 1,499 | 392 |
| 30 Jun 24 | 4,313 | 528 | 1,568 | 399 |
| 31 Mar 24 | 4,477 | 528 | 1,580 | 383 |
| 31 Dec 23 | 4,462 | 521 | 1,603 | 375 |
| 30 Sep 23 | 4,364 | 448 | 1,609 | 349 |
| 30 Jun 23 | 4,422 | 430 | 1,650 | 340 |
| 31 Mar 23 | 4,331 | 409 | 1,701 | 362 |
| 31 Dec 22 | 4,066 | 350 | 1,557 | 335 |
| 30 Sep 22 | 3,937 | 341 | 1,490 | 330 |
| 30 Jun 22 | 3,815 | 336 | 1,430 | 327 |
| 31 Mar 22 | 3,779 | 322 | 1,426 | 330 |
| 31 Dec 21 | 3,783 | 334 | 1,456 | 334 |
| 30 Sep 21 | 3,781 | 399 | 1,396 | 332 |
| 30 Jun 21 | 3,848 | 442 | 1,404 | 301 |
| 31 Mar 21 | 3,725 | 441 | 1,402 | 311 |
| 31 Dec 20 | 3,674 | 439 | 1,351 | 310 |
| 30 Sep 20 | 3,767 | 429 | 1,486 | 323 |
| 30 Jun 20 | 3,815 | 441 | 1,480 | 312 |
| 31 Mar 20 | 3,943 | 493 | 1,459 | 270 |
| 31 Dec 19 | 4,113 | 515 | 1,490 | 311 |
| 30 Sep 19 | 4,013 | 539 | 1,275 | 366 |
| 30 Jun 19 | 3,893 | 521 | 1,224 | 395 |
| 31 Mar 19 | 3,853 | 511 | 1,233 | 388 |
| 31 Dec 18 | 3,808 | 504 | 1,242 | 326 |
| 30 Sep 18 | 3,790 | 539 | 1,331 | 190 |
| 30 Jun 18 | 3,586 | 475 | 1,176 | 238 |
| 31 Mar 18 | 3,363 | 436 | 1,040 | 189 |
| 31 Dec 17 | 2,963 | 367 | 898 | 142 |
| 30 Sep 17 | 2,820 | 287 | 790 | 124 |
| 31 Dec 16 | 2,565 | 247 | 716 | 0 |
| 31 Dec 15 | 2,497 | 247 | 572 | 0 |
| 31 Dec 14 | 2,388 | 220 | 557 | 0 |
| 31 Dec 13 | 2,206 | 208 | 541 | 0 |
Kwaliteitswinsten: 603367 has high quality earnings.
Groeiende winstmarge: 603367's current net profit margins (12.4%) are higher than last year (10.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 603367's earnings have grown by 0.5% per year over the past 5 years.
Versnelling van de groei: 603367's earnings growth over the past year (18.1%) exceeds its 5-year average (0.5% per year).
Winst versus industrie: 603367 earnings growth over the past year (18.1%) exceeded the Pharmaceuticals industry -1.2%.
Rendement op eigen vermogen
Hoge ROE: 603367's Return on Equity (9.1%) is considered low.